Rankings
▼
Calendar
JAZZ Q4 2022 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q4 2022 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$972M
+8.4% YoY
Gross Profit
$805M
82.8% margin
Operating Income
-$263M
-27.1% margin
Net Income
-$240M
-24.7% margin
EPS (Diluted)
$-3.81
QoQ Revenue Growth
+3.3%
Cash Flow
Operating Cash Flow
$342M
Free Cash Flow
$333M
Stock-Based Comp.
$62M
Balance Sheet
Total Assets
$10.8B
Total Liabilities
$7.7B
Stockholders' Equity
$3.1B
Cash & Equivalents
$881M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$972M
$897M
+8.4%
Gross Profit
$805M
$761M
+5.8%
Operating Income
-$263M
$49M
-633.4%
Net Income
-$240M
-$35M
-578.8%
Revenue Segments
Xywav
$281M
29%
Xyrem
$247M
26%
Epidiolex/Epidyolex
$207M
21%
Rylaze/Enrylaze
$81M
8%
Zepzelca
$72M
7%
Defitelio/Defibrotide
$41M
4%
Vyxeos
$30M
3%
Sativex
$5M
0%
Other Products
$3M
0%
Geographic Segments
UNITED STATES
$904M
93%
Europe
$58M
6%
Other Countries
$11M
1%
← FY 2022
All Quarters
Q1 2023 →